Alte Antibiotika im neuen Glanz

Kernaussagen

• Weltweit nimmt die Zahl der sogenannten Problemkeime – Mikroorganismen mit Resistenzen gegen multiple Antibiotika – zu.

• Die Entwicklung neuer Antibiotika stagniert.

• Im klinischen Alltag ist in Zukunft mit einem häufigeren Einsatz der älteren Antibiotika zu rechnen:

  • Colistin,

  • Fosfomycin,

  • Fusidinsäure,

  • Doxycyclin und

  • Nitrofurantoin.

• Diese älteren Antibiotika weisen zwei Eigenschaften auf, die ihre Neuentdeckung begründen und rechtfertigen:

  • Wirksamkeit gegen multiresistente Problemkeime.

  • Aufgrund ihres schmalen Wirkungsspektrums oder ihrer Pharmakokinetik üben sie nur einen geringen Selektionsdruck aus und entschleunigen dadurch die Resistenzentwicklung.

• [Tab. 3] fasst die Antibiotika und ihre Einsatzgebiete zusammen.

• Literatur

• 1 Bergen PJ, Landersdorfer CB, Lee HJ et al. „Old“ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 2012; 25: 626-633
• 2 Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-1958
• 3 Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-260 ; 2nd page, table of contents
• 4 Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008; 6: 593-600
• 5 Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007; 13: 592-597
• 6 Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 52 Suppl 2011; 7: 487-492
• 7 Fernandes P, Pereira D. Efforts to support the development of fusidic acid in the United States. Clin Infect Dis 2011; 52: 542-546
• 8 Garonzik SM, Li J, Thamlikitkul V et al. Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically-Ill Patients from a Multi-Center Study Provide Dosing Suggestions for Various Categories of Patients. Antimicrob Agents Chemother 2011; 55: 3284-3294
• 9 Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-e120
• 10 IDSA. Bad Bugs, No Drugs. http://www.fda.gov/ohrms/dockets/dockets/04s0233/04s-0233-c000005-03-IDSA-vol1.pdf
• 11 Kashanian J, Hakimian P, Blute MJr et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008; 102: 1634-1637
• 12 Kastoris AC, Rafailidis PI, Vouloumanou EK et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol 2010; 66: 359-368
• 13 Li J, Nation Rl, Owen Rj et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45: 594-598
• 14 Livermore D, James D, Duckworth G et al. Fusidic-acid use and resistance. Lancet 2002; 360: 806
• 15 Monden K, Ando E, Iida M et al. Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 2002; 8: 218-226
• 16 Nelson Ml, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci 2011; 1241: 17-32
• 17 Nickel JC. Management of urinary tract infections: historical perspective and current strategies: Part 2--Modern management. J Urol 2005; 173: 27-32
• 18 Nilsson AI, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-2858
• 19 Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-3436
• 20 Powers JH. Antimicrobial drug development--the past, the present, and the future. Clin Microbiol Infect 2004; 10 (Suppl. 04) 23-31
• 21 Rattanaumpawan P, Lorsutthitham J, Ungprasert P et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65: 2645-2649
• 22 Samonis G, Maraki S, Karageorgopoulos DE et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31: 695-701
• 23 Schwartz RS. Paul Ehrlich’s magic bullets. N Engl J Med 2004; 350: 1079-1080
• 24 Shields Rk, Clancy Cj, Gillis Lm et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS 2012; One 7: e52349
• 25 Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12 (Suppl. 02) 59-66
• 26 Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl. 02) 35-44
• 27 Velkov T, Thompson PE, Nation Rl et al. Structure--activity relationships of polymyxin antibiotics. J Med Chem 2010; 53: 1898-1916
• 28 Wolfe Cr. Case report: treatment of chronic osteomyelitis. Clin Infect Dis 2011; 52 (Suppl. 07) 538-541
• 29 Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 2012; 25: 67-77